Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral (R)

Salek, M. S., Finlay, Andrew Yule ORCID: https://orcid.org/0000-0003-2143-1646, Lewis, J. J. C. and Sumner, M. I. 2004. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral (R). Quality of Life Research 13 , pp. 91-95.

Full text not available from this repository.

Abstract

Due to concern over long term safety of continuous treatment with cyclosporin, the aim of this 1 year study was to assess the effect of intermittent therapy with cylclosporin (Neoral)on the quality of life of patients suffering from chronic plaque psoriasis. A total of 40 patients with chronic plaque psoriasis (26 male,mean age:36 years,range:18-61;duration of psoriasis 17 years,range:2-31)entered a 9 centre open study in which cyclosporin was taken as an initial dose of 5mg/kg/ daily for a maximum of 12 weeks for up to three cycles. Each patient completed a psoriasis specific QOL measure (Psoriasis Disability Index PDI)at the beginning and end of each treatment cycle and at the end of study. Clinical Parameters including Psoriasis Area and Severity Index (PASI)were measured. The PDI scores showed a signigifican imporovement(p<0.01) between the beginning and end of all three treatment cycles. The various clinical assessments for each treatment period also showed significant improvement (p<0.001) for all 3 cycles. When comparing the last follow-up value to baseline there was a clear indication of relapse, but these scores were still significantly better than at baseline(p<0.01. Notably, the mean PASI score improved by more than 50%(p<0.001)between first baseline and the end of the study. These findings indicate that a short course of intermittent therapy with cyclosporin in microemulsion formulation, used ar starting doses of 5mg/kg/day, improves QOL of patients with chronic plaque psoriasis. Once again , the applicability and validity of the PDI as a useful QOL has been demonstrated.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RZ Other systems of medicine
Uncontrolled Keywords: cyclosporin,neoral,PDI,psoriasis,quality of life
Publisher: Springer Verlag
ISSN: 0962-9343
Last Modified: 27 Oct 2022 09:49
URI: https://orca.cardiff.ac.uk/id/eprint/67847

Actions (repository staff only)

Edit Item Edit Item